Enveric Biosciences Files Supplemental Proxy Materials to Correct Reverse Stock Split Ratio Range

On April 30, 2026, Enveric Biosciences, Inc. filed a Current Report on Form 8-K to supplement its definitive proxy statement originally filed on April 14, 2026. The purpose of this filing is to correct typographical errors regarding the proposed reverse stock split range in Proposal 3 for the upcoming 2026 Annual Meeting of Stockholders, scheduled for May 28, 2026. The initial proxy materials, including the proxy card and Notice of Internet Availability, incorrectly listed the maximum ratio for the reverse stock split as 1-for-50. The correct range intended by the Board of Directors is 1-for-5 to 1-for-15. This correction has been clarified in the additional proxy materials filed on Schedule 14A. All other details of the Annual Meeting, including the location, record date, and other proposals—such as the election of directors, executive compensation approval, and a proposal to increase authorized common stock from 100 million to 5 billion shares—remain unchanged. The company has engaged Kingsdale Advisors to assist with the proxy solicitation process.